

## Biden Regime Quietly Extends COVID-19 'Emergency Declaration' to Shield Big Pharma and mRNA Vaccine Makers from Liability Until 2029

By Jim Hoft Global Research, December 12, 2024 The Gateway Pundit 11 December 2024 Region: <u>USA</u> Theme: <u>Law and Justice</u>

The Biden administration has quietly extended a controversial "emergency declaration" under the Public Readiness and Emergency Preparedness (PREP) Act until December 31, 2029.

"Secretary Becerra signed the 12th amendment to the declaration under the PREP Act for COVID-19 Medical Countermeasures. The Secretary issues this amendment pursuant to section 319F-3 of the Public Health Service Act to extend the duration of the Declaration to December 31, 2029, and to republish the Declaration in full," according to the <u>announcement</u>.

The timing? Conveniently, it ensures that Big Pharma and mRNA vaccine makers remain shielded from liability throughout President Trump's second term and beyond.

According to the Federal Registrar Notice reviewed by The Gateway Pundit:

"I am now amending section XII of the Declaration to extend the time period of PREP Act coverage through December 31, 2029. COVID-19 continues to present a credible risk of a future public health emergency.

COVID-19 continues to cause significant serious illness, morbidity, and mortality during outbreaks. The risk of domestic cases is high due to ongoing outbreaks that continue domestically and internationally in the year since the PHE for COVID-19 ended.

Development of and stockpiling vaccines, therapeutics, devices, and diagnostics for COVID-19 continues to be needed for U.S. preparedness against the credible threat of a public health emergency due to outbreaks of COVID-19.

Continued coverage under the PREP Act, as provided in this Declaration, is intended to prepare for and mitigate the credible risk presented by COVID-19."

While the Biden administration insists the extension is a precaution for "future public health emergencies," critics argue it reeks of cronyism and corruption, benefiting pharmaceutical giants while sidelining the American public's growing concerns about vaccine injuries and accountability.

The PREP Act provides sweeping liability immunity for vaccine manufacturers and distributors, effectively preventing lawsuits except in cases of "willful misconduct."

By extending this declaration, Biden's Health and Human Services Department locks in protections for companies producing COVID-19 vaccines, ensuring their profits remain unscathed regardless of adverse effects or public outcry.

"Covered Persons who are afforded liability immunity under this Declaration are "manufacturers," "distributors," "program planners," "qualified persons," and their officials, agents, and employees, as those terms are defined in the PREP Act, and the United States.

"Order" as used herein and in guidance issued by the Office of the Assistant Secretary for Health means a provider medication order, which includes prescribing of vaccines, or a laboratory order, which includes prescribing laboratory orders, if required.

"Qualified person" includes (A) a licensed health professional or other individual who is authorized to prescribe, administer, or dispense such countermeasures under the law of the State in which the countermeasure was prescribed, administered, or dispensed."

The declaration provides immunity from liability for claims:

- of loss caused, arising out of, relating to, or resulting from administration or use of countermeasures to diseases, threats and conditions
- determined by the Secretary to constitute a present, or credible risk of a future public health emergency
- to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures.

Read the Notice of Amendment <u>here</u>.

\*

Click the share button below to email/forward this article to your friends and colleagues. Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

## **Global Research's Holiday Fundraiser**

**Jim Hoft** is the founder and editor of The Gateway Pundit, one of the top conservative news outlets in America. Jim was awarded the Reed Irvine Accuracy in Media Award in 2013 and is the proud recipient of the Breitbart Award for Excellence in Online Journalism from the Americans for Prosperity Foundation in May 2016. You can <u>email Jim Hoft here</u>, and <u>read</u> <u>more of Jim Hoft's articles here</u>.

Featured image is from <u>depositphotos.com</u> via TGP

The original source of this article is <u>The Gateway Pundit</u> Copyright © Jim Hoft, <u>The Gateway Pundit</u>, 2024

**Comment on Global Research Articles on our Facebook page** 

## **Become a Member of Global Research**

Articles by: Jim Hoft

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca